Idelvion

Albutrepenonacog alfa, the active ingredient in Idelvion, is a recombinant factor VIII presented as a solution for injection for intravenous use. It treats hemophilia A by replacing the deficient clotting factor in patients with the disorder.

GNH USA supplies Idelvion as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Idelvion is a recombinant factor VIII used in the coagulation pathway for hemophilia A management.

- Prophylaxis of bleeding episodes in patients with hemophilia A: reduces the frequency of spontaneous bleeds and joint damage. - On‑demand treatment of acute bleeding episodes in hemophilia A: provides rapid factor replacement to stop active bleeding. - Surgical prophylaxis in hemophilia A patients: maintains hemostasis during operative procedures.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills) - Headache - Fever - Nausea

Serious or Rare Side Effects: - Development of neutralizing inhibitors (anti‑factor VIII antibodies) - Anaphylaxis - Thromboembolic events

Before initiating therapy, clinicians should consider several safety measures. - Bleeding risk assessment: evaluate baseline factor VIII activity prior to infusion. - Inhibitor monitoring: test periodically for anti‑factor VIII antibodies. - Surgical planning: coordinate dosing with the operative team to ensure adequate hemostasis. - Pregnancy and lactation: use only if the anticipated benefit outweighs potential risk. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Idelvion may interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid): - Concurrent use of bypassing agents (e.g., activated prothrombin complex concentrates) may increase thrombosis risk. - High‑dose immunoglobulin therapy may interfere with factor VIII activity.

Moderate Interactions (Monitor Closely): - Antifibrinolytics such as tranexamic acid may enhance hemostatic effect. - Certain antibiotics (e.g., rifampin) may alter clearance of the protein. - Intravenous vaccines administered close to infusion may affect immune response.